Bayer teams up with Huma to apply AI to lung cancer diagnosisA research project between Bayer and digital health company Huma will use artificial intelligence to detect lung cancer Share XBayer teams up with Huma to apply AI to lung cancer diagnosishttps://pharmaphorum.com/news/bayer-teams-up-with-huma-to-apply-ai-to-lung-cancer-diagnosis/
Sanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancerSanofi and Regeneron’s latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche Share XSanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancerhttps://pharmaphorum.com/news/sanofi-regeneron-eye-libtayo-challenge-to-merck-in-first-line-lung-cancer/
Roche gets fast FDA review for Tecentriq in adjuvant lung cancerRoche is preparing for a December verdict from the FDA on adjuvant use of its PD-L1 inhibitor Tecentriq Share XRoche gets fast FDA review for Tecentriq in adjuvant lung cancerhttps://pharmaphorum.com/news/roche-gets-fast-fda-review-for-tecentriq-in-adjuvant-lung-cancer/
Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
Arcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckonsArmed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme Share XArcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckonshttps://pharmaphorum.com/news/arcus-preps-more-phase-3-trials-for-tigit-antibody-as-gilead-opt-in-beckons/
AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLCAstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share XAZ, HutchMed’s savolitinib gets 1st approval in China for NSCLChttps://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/
Heat Bio’s shares ignite on Opdivo combination data in NSCLCThe pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival Share XHeat Bio’s shares ignite on Opdivo combination data in NSCLChttps://pharmaphorum.com/news/heat-bios-shares-ignite-on-opdivo-combination-data-in-nsclc/
Roche nabs breakthrough tag for TIGIT cancer immunotherapyRoche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough Share XRoche nabs breakthrough tag for TIGIT cancer immunotherapyhttps://pharmaphorum.com/news/roche-nabs-breakthrough-tag-for-tigit-cancer-immunotherapy/
J&J files lung cancer bispecific amivantamab for FDA approvalJohnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big Share XJ&J files lung cancer bispecific amivantamab for FDA approvalhttps://pharmaphorum.com/news/jj-files-lung-cancer-bispecific-amivantamab-for-fda-approval/
